Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono Extends CNS Collaboration With Newron, Invests In Israel

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.

You may also be interested in...

Corporate Venture Eyes The Early Stage

In our second annual Life Science Venture Survey, VCs paid their respects to the importance of corporate investors right now. For their part, corporate investors, many from long-established programs, said they are bullish about making more bets in early-stage companies.

Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.

Lilly Adds Dual-Acting Insomnia Compound With Acquisition Of Hypnion

Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts